/ Weight Loss Drugs
/ Market Analysis
Why Is Novo Nordisk Stock Down 13% Premarket? Trial Fails to Match Eli Lilly
Novo Nordisk stock plunged over 13% in premarket trading after its experimental obesity drug CagriSema failed to prove non-inferiority to Eli Lilly's ...
February 23, 2026
Eli Lilly’s Stock Soars After Weight-Loss Pill Competing with Ozempic Shows Promise
Eli Lilly's new weight-loss pill, matches Ozempic in effectiveness.
April 17, 2025
Wall Street Weighs in as Pfizer Targets $100 Billion Weight Loss Market
Pfizer announced plans to advance a once-daily version of its weight loss pill, danuglipron, following encouraging early-stage trial results.
July 11, 2024
Back to 
